Aceso Life Science Group Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	8yrs
Promedio de permanencia en la Junta Directiva	12.3yrs

Actualizaciones recientes de la dirección

Recent updates

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Feb 23

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Jan 01

CEO

Aceso Life Science Group no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Chi Tak Fok	CFO & Executive Director	13.9yrs	HK$5.00m	0.82% HK$ 3.5m
Shao Yu Li	Senior Consultant	9.2yrs	HK$13.20m	57.5% HK$ 246.2m
Zhiliang Ou	Executive Director	no data	HK$600.00k	0.0099% HK$ 42.6k
Xiaodong Liu	Chief Operating Officer	6.2yrs	sin datos	sin datos
Chun Mo Law	Group Financial Controller	8yrs	sin datos	sin datos
Chun Pong Siu	Company Secretary	2.3yrs	sin datos	sin datos

8.0yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 474 es experimentado (8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Chi Tak Fok	CFO & Executive Director	11.2yrs	HK$5.00m	0.82% HK$ 3.5m
Zhiliang Ou	Executive Director	12.4yrs	HK$600.00k	0.0099% HK$ 42.6k
Kwan Sing Lam	Independent Non-Executive Director	12.3yrs	HK$200.00k	0.0099% HK$ 42.6k
Ming Sun Chan	Independent Non-Executive Director	12.7yrs	HK$200.00k	0.0099% HK$ 42.6k
Yiu Tong Mak	Independent Non-Executive Director	3.3yrs	HK$200.00k	sin datos

12.3yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 474 son experimentados ( 12.3 años antigüedad media).

Aceso Life Science Group Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Aceso Life Science Group Limited, Annual General Meeting, Sep 19, 2024

Aceso Life Science Group Limited Announces Resignation of Xu Haiying as Executive Director

Aceso Life Science Group Limited, Annual General Meeting, Sep 15, 2023

Aceso Life Science Group Limited Announces Change of Company Secretary

Aceso Life Science Group Limited, Annual General Meeting, Sep 16, 2022

Recent updates

New minor risk - Share price stability

Insufficient new directors

Full year 2024 earnings released: HK$0.064 loss per share (vs HK$0.036 loss in FY 2023)

Aceso Life Science Group Limited, Annual General Meeting, Sep 19, 2024

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Aceso Life Science Group Limited to Report Fiscal Year 2024 Final Results on Jun 26, 2024

Aceso Life Science Group Limited Announces Resignation of Xu Haiying as Executive Director

First half 2024 earnings released: HK$0.028 loss per share (vs HK$0.007 loss in 1H 2023)

New major risk - Revenue size

Aceso Life Science Group Limited Provides Group Earnings Guidance for the Six Months Ended 30 September 2023

Aceso Life Science Group Limited to Report First Half, 2024 Results on Nov 28, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited, Annual General Meeting, Sep 15, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited to Report Fiscal Year 2023 Results on Jun 28, 2023

New minor risk - Market cap size

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

Aceso Life Science Group Limited Consolidated Earnings Guidance for the Six Months Ended 30 September 2022

Aceso Life Science Group Limited to Report First Half, 2023 Results on Nov 29, 2022

Aceso Life Science Group Limited (SEHK:474) agreed to acquire 4% stake in Quanzhou Donghai Bay Asset Management Company Limited for approximately CNY180 million.

Aceso Life Science Group Limited Announces Change of Company Secretary

Full year 2022 earnings released: HK$0.051 loss per share (vs HK$0.057 loss in FY 2021)

Aceso Life Science Group Limited, Annual General Meeting, Sep 16, 2022

Full year 2022 earnings released

Aceso Life Science Group Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Aceso Life Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2022

Senior Consultant recently bought HK$18m worth of stock

Senior Consultant recently bought HK$4.6m worth of stock

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Non-Executive Director Yao Li has left the company

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Senior Consultant recently sold HK$5.0m worth of stock

First half 2021 earnings released: HK$0.07 loss per share

New 90-day low: HK$0.23

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.07 loss per share

Aceso Life Science Group Limited to Report First Half, 2021 Results on Nov 25, 2020

New 90-day low: HK$0.28

Senior Consultant recently bought HK$852k worth of stock

Hao Tian Development Group Limited has completed a Follow-on Equity Offering in the amount of HKD 150 million.

Senior Consultant recently bought HK$2.8m worth of stock

New 90-day high - HK$0.34

Full year earnings released - HK$0.049 loss per share

Hao Tian Development Group Limited to Report Fiscal Year 2020 Results on Jun 29, 2020

CEO

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad